A little over two months ago, the Dow Jones Industrial Average was sitting at 15,660.18–down 8.3% for 2016–and investors were freaking out about the end of the world. Now it’s back above 18,000, having gained 15% in just nine-and-a-half weeks.
The Dow Jones Industrial Average rose106.70 points, or 0.6%, to18,004.16 today, it’s highest close since July 20, 2015. The S&P 500 gained 0.7% to 2,094.34, while the Nasdaq Composite advanced 0.4% to 4,960.02.
The bigger surprise is that the Dow retook that milestone despite the fact that Opec couldn’t reach a deal to freeze oil production. Strategas Research Partners’ Daniel Clifton and team have an idea why the lack of agreement hasn’t been a bid deal for the market:
Yesterday OPEC and other major oil producers failed to reach an agreement to freeze oil production levels. The potential deal was viewed as a possible first step in what could lead to later discussions to cut production. A deal off the table, at least for the time being, suggests that the oil market will take later than expected for it to rebalance supply and demand. What we are seeing is a lesson in the free market, courtesy of Saudi Arabia. An agreement seems difficult to reach as long as Iranian oil is coming back on line, Iraq and Russia are gaining market share, and US shale production remains elevated. There are signs that US production is slowing but the Saudis are probably waiting to see further cuts in US production before moving forward should Iran not be included in a deal. This will no doubt continue the pain trade in oil, EM, high-yield, and possibly even stocks. But the effects of these OPEC decisions are getting smaller since some of the imbalances are being worked out and the dollar seems to have topped out.
5 Best Undervalued Stocks To Buy Right Now: Fogo de Chao, Inc.(FOGO)
Fogo de Chao, Inc., incorporated on May 24, 2012, is a holding company. The Company operates Brazilian churrascaria steakhouses under the brand of Fogo de Chao. The Company operates through two segments: the United States and Brazil. The Company is specialized in fire-roasting meats utilizing the Southern Brazilian cooking technique of churrasco. It delivers Brazilian dining experience through the combination of its Brazilian cuisine and its service model known as espeto corrido (Portuguese for continuous service) delivered by its gaucho chefs. The Company offers its guests with entree service table-side, which is available at each guest’s seat, green side up from its gaucho chefs. Each gaucho chef rotates throughout the dining room, and is responsible for a specific cut of meat, which they prepare, cook and serve to its guests throughout their meal. The Company operates over 30 restaurants in the United States and over 10 restaurants in Brazil, and a joint venture restaur ant in Mexico.
The Company’s menu consists of steak, including picanha, filet mignon, beef ancho, alcatra, fraldinha and costela; chicken, lamb and pork, including cordeiro, costela de porco, frango, lombo and linguica; seafood, including smoked salmon, jumbo shrimp cocktail and grilled spiced shrimp skewers; side dishes, including spring pea and asparagus soup, garlic mashed potatoes, caramelized bananas, pao de queijo, farofa, polenta, fogo feijoada and sauces; market table, including edamame roasted corn salad (seasonal), forbidden black rice salad (seasonal), hearts of palm, black pepper candied bacon, chicken salad and cold smoked salmon; desserts, including papaya cream, strawberry cream, caramelized pineapple and chocolate mousse cake, and bar fogo, including picanha sirloin slider, charcuterie board, grilled spiced shrimp skewers, mango refresco and superfruit lemonade. The Company’s menu also includes wines, such as Lapostolle, Merlot; Belle Glos, Pinot Noir; Lapostolle, Merlot, Rapel Valley, and Silver Oak, Cab! ernet Sauvignon.
- [By Monica Gerson]
Fogo De Chao Inc (NASDAQ: FOGO) is expected to post its quarterly earnings at $0.28 per share on revenue of $76.80 million.
Constellium NV (NYSE: CSTM) is estimated to report its quarterly earnings at $0.06 per share on revenue of $1.18 billion.
5 Best Undervalued Stocks To Buy Right Now: Silver Wheaton Corp(SLW)
Silver Wheaton Corp., together with its subsidiaries, operates as a silver streaming company worldwide. The company has 14 long-term silver purchase agreements and 2 long-term precious metal purchase agreements whereby it acquires silver and gold production from the counterparties located in Mexico, the United States, Canada, Greece, Sweden, Peru, Chile, Argentina, and Portugal. Silver Wheaton Corp. is headquartered in Vancouver, Canada.
- [By Monica Gerson]
Silver Wheaton Corp. (USA) (NYSE: SLW) is estimated to post its quarterly earnings at $0.13 per share on revenue of $178.33 million.
eLong, Inc. (ADR) (NASDAQ: LONG) is projected to post a quarterly loss at $0.60 per share on revenue of $38.31 million.
10 Best Chemical Stocks To Invest In Right Now: Sony Corp Ord(SNE)
Sony Corporation designs, develops, manufactures, and sells electronic equipment, instruments, and devices for consumer, professional, and industrial markets worldwide. The company offers consumer products and devices, including televisions, video cameras, compact digital cameras and interchangeable single-lens cameras, Blu-ray Disc players/recorders, DVD-video players/recorders, home theaters and audio systems, and portable audio and car audio products. It also provides charged coupled devices, complementary metal-oxide semiconductor image sensors, system LSIs, small- and medium-sized LCD panels, and other semiconductors; and components, such as batteries, optical disk drives, chemical products, audio/video/data recording media, storage media, and optical pickups. In addition, the company develops, produces, markets, and distributes games, such as PlayStation3, PlayStation Portable, and PlayStation 2 hardware and related software; and PCs and flash memory digital audio pl ayers, as well as manufactures broadcast- and professional-use products, Blu-ray discs, DVDs, and CD discs. Further, it produces and distributes motion pictures and television programs, and home entertainment; creates and distributes digital content; operates television networks and studio facilities; and develops entertainment products, services, and technologies. Additionally, the company engages in the music publishing business, as well as provision of various financial services, including insurance, savings products, loans, and credit financing services; and a network service business and an advertising agency business. It also involves in research, development, design, production, marketing, sales, distribution, and servicing mobile phones, accessories, services, and applications. The company was formerly known as Tokyo Tsushin Kogyo Kabushiki Kaisha and changed its name to Sony Corporation in 1958. Sony Corporation was founded in 1946 and is based in Tokyo, Japan.
- [By Christopher Freeburn]
Here are four things to know about Grand Theft Auto V:
It is available for both Sony‘s (SNE) Playstation 3 and Microsoft‘s (MSFT) Xbox 360 consoles. It is set in a fictionalized urban landscape based on Los Angeles. It offers three main characters, unlike prior editions, which focused on one. Rockstar Games will launch an online version — Grand Theft Auto Online — next month.
Nintendo Still Wont Make a Cash Grab for Mobile Games
Yesterday, Amazon (AMZN) said that it had sold out its pre-orders of Grand Theft Auto V for Xbox consoles, though some copies for the Playstation were still available.
- [By Jack Grant]
Currently, “Transformers 7” is the only inhabitant of its June 29, 2019 release date, although that would sandwich it between Walt Disney Co (NYSE: DIS’s “The Incredibles 2” and Sony Corp (ADR) (NYSE: SNE)’s “Bad Boys 4.”
5 Best Undervalued Stocks To Buy Right Now: Amgen Inc.(AMGN)
Amgen Inc., a biotechnology medicines company, discovers, develops, manufactures, and markets human therapeutics based on advances in cellular and molecular biology for grievous illnesses primarily in the United States, Europe, and Canada. The company markets recombinant protein therapeutics in supportive cancer care, nephrology, and inflammation. Its principal products include Aranesp and EPOGEN erythropoietic-stimulating agents that stimulate the production of red blood cells; Neulasta and NEUPOGEN to stimulate the production of neutrophils, which is a type of white blood cell that helps the body to fight infections; and Enbrel, an inhibitor of tumor necrosis factor that plays a role in the body?s response to inflammatory diseases. The company also markets other products comprising Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin (TPO) receptor agonist that mimics endogenous TPO, the primary driver of platelet production. In addition, it provides Denosumab, a human monoclonal antibody that targets RANKL, an essential regulator of osteoclasts. Further, the company offers product candidates in mid-to-late stage development in a variety of therapeutic areas, including oncology, hematology, inflammation, bone, nephrology, cardiovascular, and general medicine consisting of neurology. It markets its products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies; consumers; and wholesale distributors of pharmaceutical products. The company has various collaborative arrangements with Pfizer Inc.; GlaxoSmithKline plc; Takeda Pharmaceutical Company Limited; Daiichi Sankyo Company, Limited; Array BioPharma Inc.; Kyowa Hakko Kirin Co. Ltd.; and Cytokinetics, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
- [By Keith Speights]
Amgen (NASDAQ: AMGN ) is another company that’s probably keeping track of what’s going on. The more successful Keryx is with Zerenex, the fewer possible sales for Amgen’s Epogen.
- [By Ben Levisohn]
Reports suggest that Gilead Sciences (GILD) and Celgene (CELG) have joined the bidding process forMedivation (MDVN), one that already includes (maybe) Amgen (AMGN), and of course Sanofi (SNY), which is trying to throw out Medivation’s board. Of the three biotech giants, Citigroup’s Robyn Karnauskas and team argue that Amgen is best positioned to win the battle. They explain why:
- [By Ben Levisohn]
Well, it looks like Medivation (MDVN) now has five suitors after reports that Amgen (AMGN) is joining Pfizer (PFE), Sanofi (SNY), AstraZeneca (AZN) and Novartis (NVS) in considering a bid. Maxim’s Jason Kolbert and Jason McCarthy offer their thoughts:
5 Best Undervalued Stocks To Buy Right Now: Medidata Solutions, Inc.(MDSO)
Medidata Solutions, Inc. provides cloud-based clinical development solutions for life sciences in the United States and internationally. The company offers applications and data analytics for clinical development. It offers Medidata Rave, a platform for capturing, managing, and reporting clinical data; Medidata CTMS, a clinical trial management solution that streamlines operational workflows; Medidata Designer, which enhances the efficiency of clinical trial start-up; Medidata Insights, a clinical business analytics platform; and Medidata Balance, a randomization and trial supply management solution. The company also provides Medidata Patient Cloud application for electronic patient-reported outcome; Medidata Grants Manager, which enables to develop and manage trial budgets; Medidata contract research organization (CRO) Contractor, an analytical tool for CRO outsourcing, budgeting, and negotiation; and Medidata SQM, a set of c loud-based site quality management dashboards. In addition, it offers Medidata Coder that provides medical coding and synonym management solutions; Medidata Safety Gateway, which offers a solution for collecting and transmitting adverse events and related data from the EDC system; and Medidata Targeted SDV that provides auditable and scalable solutions, as well as offers hosting, support, and professional services. Medidata Solutions, Inc. markets and sells its cloud-based solutions through direct sales force, as well as through relationships with CROs and other strategic partners. The company serves pharmaceutical, biotechnology, medical device, and diagnostics companies; and academic institutions, contract research organizations, and other entities engaged in clinical trials. Medidata Solutions, Inc. was founded in 1999 and is headquartered in New York, New York.
- [By Lisa Levin]
On Wednesday, technology shares climbed by 0.94 percent. Top gainers in the sector included Marvell Technology Group Ltd. (NASDAQ: MRVL) and Medidata Solutions Inc (NASDAQ: MDSO).